A5013926915- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
- Polyomavirus and related diseases
- Viral-associated cancers and disorders
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Oral health in cancer treatment
- Renal Transplantation Outcomes and Treatments
- Venous Thromboembolism Diagnosis and Management
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Retinoids in leukemia and cellular processes
- Chemotherapy-induced cardiotoxicity and mitigation
- CNS Lymphoma Diagnosis and Treatment
- Mesenchymal stem cell research
Case Western Reserve University
2016-2025
University Hospitals of Cleveland
2016-2025
Case Comprehensive Cancer Center
2007-2025
University School
2024
University Hospitals Seidman Cancer Center
2015-2024
Cleveland Clinic
2021-2024
Cancer Institute (WIA)
2024
University Hospitals Cleveland Medical Center
2010-2019
University of Toledo
2012
Memorial Sloan Kettering Cancer Center
2010
Multipotential mesenchymal stem cells (MSCs) are found in human bone marrow and shown to secrete hematopoietic cytokines support progenitors vitro. We hypothesized that infusion of autologous MSCs after myeloablative therapy would facilitate engraftment by cells, we investigated the feasibility, safety, effects culture-expanded breast cancer patients receiving peripheral-blood progenitor-cell (PBPC) infusion.We developed an efficient method isolating culture-expanding a homogenous population...
Mesenchymal stem cells (MSCs) are found in a variety of tissues, including human bone marrow; secrete hematopoietic cytokines; support progenitors vitro; and possess potent immunosuppressive properties. We hypothesized that cotransplantation culture-expanded MSCs (HSCs) from HLA-identical sibling donors after myeloablative therapy could facilitate engraftment lessen graft-versus-host disease (GVHD); however, the safety feasibility this approach needed to be established. In an open-label,...
Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) time. This study used central database Center for International Blood Marrow Transplant Research (CIBMTR) to describe time cGVHD incidence, nonrelapse mortality, risk factors cGVHD. The 12-year period was divided into 3 intervals, 1995 1999, 2000 2003, 2004 2007, included 26,563 patients with acute leukemia, myeloid...
Abstract Allogeneic hematopoietic cell transplant is a potential curative therapy for acute lymphoblastic leukemia (ALL). Delineating the graft-versus-leukemia (GVL) effect as function of graft-versus-host disease (GVHD) offers to improve survival. We examined 5215 recipients with ALL reported Center International Blood and Marrow Transplant Research registry. Overall survival (OS) was compared according presence severity GVHD evaluated in 3 cohorts: 2593 adults first or second complete...
Gilteritinib is a type 1 FLT3 inhibitor active as monotherapy for relapsed or refractory FLT3-mutated AML. We investigated the safety, tolerability, and efficacy of gilteritinib incorporated into intensive induction consolidation chemotherapy, maintenance therapy adult patients with newly diagnosed, non-favorable-risk AML.In this phase IB study (2215-CL-0103; ClinicalTrials.gov identifier: NCT02236013), 103 participants were screened 80 allocated to treatment. The was divided four parts:...
The curative potential of allogeneic hematopoietic transplantation (allo-HCT) in patients with acute lymphoblastic leukemia (ALL) is hampered by relapse. Inotuzumab ozogamicin (INO) an anti-CD22 monoclonal antibody bound to calicheamicin, which has significant activity against ALL. We hypothesized that low-dose INO would be safe and feasible after allo-HCT. Therefore, we conducted a phase 1 study determine the dose safety this setting. Patients were eligible if they aged 16 75 years, had...
There is an increased risk of infection in patients with cancer that results higher morbidity and mortality. Several factors can predispose these to infectious complications. Some such include immunocompromised states like neutropenia, allogeneic hematopoietic cell transplantation, graft-versus-host disease, while others immunosuppressive agents corticosteroids, purine analogs, monoclonal antibodies, other emerging therapeutics CAR T-cell therapy. The NCCN Guidelines for the Prevention...
PURPOSE: To assess the antitumor activity, safety, and hormone-suppressive effects of irreversible aromatase inactivator, exemestane (Aromasin, Pharmacia & Upjohn, Kalamazoo, MI), administered as third-line hormone therapy to postmenopausal women with metastatic breast cancer that is refractory tamoxifen megestrol acetate. PATIENTS AND METHODS: Exemestane was at a dose 25 mg/d orally until patients experienced disease progression. The efficacy safety were clinically radiographically...
The recent approval of bortezomib for the treatment mantle cell lymphoma (MCL) by US Food and Drug Administration is based on results multicentre PINNACLE study with supportive data from a number single Phase 2 studies. This enrolled 40 patients heavily pretreated MCL. overall response rate (ORR) was 47%, including 5 complete remissions 14 partial remissions. Overall, these are relatively durable. ORR in relapsed refractory 50% 43% respectively (P = 0.74), while both populations exhibited...
PURPOSE: Patient response to hematopoietic progenitor-cell mobilizing regimens seems vary considerably, making comparison between difficult. To eliminate this inter-patient variability, we designed a cross-over trial and prospectively compared the number of progenitors mobilized into blood after granulocyte-macrophage colony-stimulating factor (GM-CSF) days 1 12 plus granulocyte (G-CSF) 7 (regimen G) with cyclophosphamide G-CSF 3 14 C) in same patient. PATIENTS AND METHODS: Twenty-nine...
We determined the toxicity and efficacy of a new preparative autologous bone marrow transplantation (ABMT) regimen in patients with relapsed or refractory non-Hodgkin's lymphoma Hodgkin's disease.Forty-four 35 disease 16 to 63 years age were given intravenous carmustine (BCNU) 600 1,050 mg/m2, etoposide 2,400 3,000 cisplatin 200 mg/m2 (BEP) ABMT. Fifty-nine also received 15 20 Gy local radiation (involved-field radiotherapy [RI]) active previously bulky (> 5 cm) sites.Nonhematologic...
Bryostatin 1, isolated from a marine bryozoan, enhances the efficacy of cytotoxic agents through modulation protein kinase C pathway and is active in combination with vincristine for diffuse large B-cell lymphoma. Further, apoptotic frequency peripheral blood T lymphocytes as determined by flow cytometry may predict which patients will respond to this combination. We tested safety bryostatin 1 50 microg/m(2) given over 24 hr 1.4 mg/m(2) on days 15 every 28 aggressive non-Hodgkin lymphoma...
Abstract Purpose: The prognosis of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remains poor, and novel therapies are needed. proteasome pathway represents a potential therapeutic target. A phase I trial the second-generation inhibitor ixazomib in combination MEC (mitoxantrone, etoposide, cytarabine) was conducted R/R AML. Patients Methods: Dose escalation performed using standard 3 × design. Gene-expression profiling on pretreatment posttreatment bone marrow or blood...
Microbiome dysbiosis has been associated with adverse outcomes of hematopoietic cell transplantation (HCT). We hypothesized that exposure to high-dose melphalan and antimicrobials in patients undergoing autologous HCT for plasma disorders results oral gastrointestinal microbial dysbiosis, which turn is regimen-related toxicities. conducted a prospective study describing the longitudinal changes bacteriome mycobiome this patient population. Our findings show microbiome composition present at...
The administration of allogeneic natural killer (NK) cells following a lymphodepleting chemotherapy regimen is emerging as well-tolerated therapeutic approach in the management various malignancies. Contrary to expected complications T cell therapy, there remains no evidence graft-versus-host disease (GVHD) mediated by NK numerous clinical trials. On contrary, preclinical and studies suggest that do not induce GVHD fact may prevent its development hematopoietic transplantation (HCT). In this...
To determine whether occult tumor contamination of autologous bone marrow or peripheral-blood progenitor cells (PBPC) influences clinical outcome after high-dose chemotherapy in patients with stage IV breast cancer.We used an immunocytochemical assay capable detecting one cell 5 x 10(5) hematopoietic to analyze and/or PBPC collections obtained from 57 consecutive women chemotherapy-sensitive metastatic cancer who received chemotherapy. The influence on time progression, overall survival, and...
PURPOSE A phase I dose-escalation study of ifosfamide, carboplatin, and etoposide (ICE) with autologous stem-cell rescue (ASCR) was conducted to determine the maximum-tolerated dose (MTD) ICE given over 6 days. PATIENTS AND METHODS One hundred fifty-four patients a variety poor-prognosis malignancies received escalating doses ifosfamide 6,000 24,000 mg/m2, carboplatin 1,200 2,100 1,800 3,000 mg/m2 divided Mesna administered in equal ifosfamide. ASCR performed 48 hours after completion ICE....
To determine the antitumor activity of novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma.Patients follicular lymphoma (FL), marginal zone lymphoma, mantle cell small lymphocytic lymphoma/chronic leukemia, and Waldenstrom's macroglobulinemia were eligible for study. Bortezomib was given at a dose 1.5 mg/m(2) as an i.v. push on days 1, 4, 8, 11 21-day cycle. Eligibility included following: (a) no more than three prior therapies, (b) least 1 month since...